about
Congenital and acquired thrombotic risk factors in lymphoma patients bearing upper extremities deep venous thrombosis: a preliminary reportDistribution of human beta-defensin polymorphisms in various control and cystic fibrosis populationsActivity of mannose-binding lectin in centenariansGenetic modifiers of liver disease in cystic fibrosis.MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection.Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis?Genotype-phenotype correlation in cystic fibrosis: the role of modifier genes.Haemophilia B: from molecular diagnosis to gene therapy.Different outcome of six homozygotes for prothrombin A20210A gene variantHaemophilia A: molecular insights.Pre-analytical stability of the plasma proteomes based on the storage temperature.Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.Congenital diarrheal disorders: improved understanding of gene defects is leading to advances in intestinal physiology and clinical management.A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.Omics in laboratory medicine.An update on laboratory diagnosis of liver inherited diseases.Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.Ledipasvir : a novel synthetic antiviral for the treatment of HCV infection.ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection.Genetic diseases that predispose to early liver cirrhosis.Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies.Biological role of mannose binding lectin: From newborns to centenarians.Molecular and functional analysis of the large 5' promoter region of CFTR gene revealed pathogenic mutations in CF and CFTR-related disorders.Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis.Five human phenylalanine hydroxylase proteins identified in mild hyperphenylalaninemia patients are disease-causing variants.The Italian pilot external quality assessment program for cystic fibrosis sweat test.The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity.Multivariate discriminant analysis of biochemical parameters for the differentiation of clinically confounding liver diseases.Severe liver impairment in a cystic fibrosis-affected child homozygous for the G542X mutation.Exploitation of a very small peptide nucleic acid as a new inhibitor of miR-509-3p involved in the regulation of cystic fibrosis disease-gene expression.Genotype-dependency of butyrate efficacy in children with congenital chloride diarrhea.Haplogroup T is an obesity risk factor: mitochondrial DNA haplotyping in a morbid obese population from southern Italy.Mannose-binding lectin genetic analysis: possible protective role of the HYPA haplotype in the development of recurrent urinary tract infections in men.Extensive molecular analysis of patients bearing CFTR-related disorders.TrkB gene expression and DNA methylation state in Wernicke area does not associate with suicidal behavior.Prenatal diagnosis of cystic fibrosis: an experience of 181 cases.Increased BDNF promoter methylation in the Wernicke area of suicide subjects.Pediatric portal vein thrombosis: more on thrombophilic risk factors.Aberrant F8 gene intron 1 inversion with concomitant duplication and deletion in a severe hemophilia A patient from Southern Italy.Carcinoembryonic antigen mRNA analysis detects micrometastatic cells in blood from lung cancer patients.
P50
Q24806536-A441A2A9-4CCE-43A1-8412-AFEEFC802541Q28244289-9D57A9D9-879D-42C7-9906-3AB51240F61DQ28257298-54973CAA-A0C4-40A3-A1D9-0BF67F7B625EQ30418279-4964E1BB-45B2-474D-A806-679D5A5E3ADDQ34411907-DF7B2500-B5BD-42D2-A686-98B7C33143AFQ34653919-B2A0FAED-1AEE-4A42-83E9-083A5CF57663Q34747403-BE2EB750-A3CC-471F-9AF4-AC0CB9AA40ECQ35127766-192F5929-FCE4-4065-AD8F-B0C4A70EDDECQ36789863-6CFF1B04-35CA-42EA-857B-1C78C55BB034Q36793856-EB052605-62EA-4239-A14C-0DE28623F746Q36858663-771021FE-379E-4079-A019-F7D5386529D8Q37411369-86937582-A85B-4761-A895-F9F3DF1DE0F5Q37705852-0E70FD51-0CCB-4E03-8547-FCDA30D0AC47Q38121160-F2A36C04-BE52-4B3E-95AE-CA3BEBB19BB7Q38141078-8A67A77D-9956-4DF1-8C94-E397B2CCD1EFQ38162187-7D7F13B3-3949-4DC7-AA9A-D82AD07C074CQ38174092-CF70764E-26F6-4F99-97F4-E4CB09E156D1Q38193198-890F32B3-9020-4FFF-B0D9-4DB376F259A4Q38227425-196E3FCF-AF0D-4F9E-8DDD-002E5F48C715Q38240870-6757347E-F718-4A85-A941-BDEEA9075490Q38381588-E2680817-0A1E-42F1-9BF4-12D5799B3903Q38381914-BA1CBCDF-22DA-428C-A86B-88841908D6D9Q39183676-DB72B25E-FD79-47EB-89EC-F260298E3CA5Q39251078-8E4490BA-C882-4F18-8FFF-FB02E80A01D3Q40001669-95B5ACDB-3FB0-41D0-89E6-FD157930FD13Q40018478-24ABAA63-D1FA-4C93-B660-BBB35DDEF0CEQ40240942-1056268B-C2A0-41ED-9F76-B6F388A4AC9DQ41348256-F9B72B0C-00E3-4B1E-B143-1937A22BFB75Q41369290-949913D7-9B87-462B-AD3B-FA10F9800FF6Q41451941-CD908744-DDA5-49B6-AE5D-32B42DA05199Q41845952-D017FBEB-1119-4F9A-92A7-CC8B6DE6DBB6Q41907812-9B30C895-FABF-4608-88FC-E4E5EC249E96Q42250143-4AC893E0-85CA-4BD1-A2F1-B9EF8A6D2373Q43434226-7CDDF876-C24B-4ED6-B22A-9581064AE703Q43750417-CCBEC908-D5C0-4F9D-AE48-D956A8A20DE5Q43769052-3A98D3E7-6AA8-4C3C-B22A-D53B52182021Q43859691-1B4F77C7-2594-433D-A81F-7477D3EE1B8CQ44420160-5285872E-97C4-4699-B95D-2BD282724DD8Q44452159-CCDF57FE-3DC2-48AA-B7DD-AED560559C5FQ44600692-0BC1F15F-A166-4F12-967D-C698C2D74281
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Giuseppe Castaldo
@ast
Giuseppe Castaldo
@en
Giuseppe Castaldo
@es
Giuseppe Castaldo
@nl
Giuseppe Castaldo
@sl
type
label
Giuseppe Castaldo
@ast
Giuseppe Castaldo
@en
Giuseppe Castaldo
@es
Giuseppe Castaldo
@nl
Giuseppe Castaldo
@sl
prefLabel
Giuseppe Castaldo
@ast
Giuseppe Castaldo
@en
Giuseppe Castaldo
@es
Giuseppe Castaldo
@nl
Giuseppe Castaldo
@sl
P106
P1153
7004623394
P21
P31
P496
0000-0002-4036-0874